X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50264) 50264
Magazine Article (460) 460
Book / eBook (48) 48
Book Review (27) 27
Conference Proceeding (13) 13
Web Resource (12) 12
Book Chapter (10) 10
Dissertation (8) 8
Newsletter (6) 6
Publication (6) 6
Government Document (4) 4
Streaming Video (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45699) 45699
anti-bacterial agents - therapeutic use (25952) 25952
female (22846) 22846
male (22138) 22138
anti-bacterial agents - adverse effects (19617) 19617
middle aged (14366) 14366
adult (14174) 14174
anti-bacterial agents - administration & dosage (12171) 12171
aged (11450) 11450
antibiotics (8550) 8550
treatment outcome (8186) 8186
anti-bacterial agents - pharmacology (6436) 6436
animals (6330) 6330
adolescent (6107) 6107
pharmacology & pharmacy (5980) 5980
infectious diseases (5825) 5825
risk factors (5318) 5318
child (5306) 5306
microbiology (4809) 4809
retrospective studies (4785) 4785
aged, 80 and over (4219) 4219
health aspects (4084) 4084
infections (4052) 4052
surgery (3940) 3940
child, preschool (3578) 3578
medicine, general & internal (3563) 3563
infection (3508) 3508
microbial sensitivity tests (3378) 3378
infant (3201) 3201
drug therapy, combination (3181) 3181
time factors (3155) 3155
prospective studies (3112) 3112
bacterial infections - drug therapy (2795) 2795
young adult (2775) 2775
therapy (2723) 2723
care and treatment (2699) 2699
management (2659) 2659
analysis (2644) 2644
anti-bacterial agents - pharmacokinetics (2461) 2461
research (2446) 2446
bacteria (2370) 2370
pediatrics (2361) 2361
immunology (2306) 2306
drug therapy (2284) 2284
diagnosis (2192) 2192
children (2189) 2189
drug resistance, bacterial (2167) 2167
infant, newborn (2148) 2148
follow-up studies (2146) 2146
mortality (2111) 2111
medicine & public health (2010) 2010
abridged index medicus (1982) 1982
internal medicine (1888) 1888
vancomycin (1861) 1861
staphylococcal infections - drug therapy (1849) 1849
anti-bacterial agents (1836) 1836
gastroenterology & hepatology (1806) 1806
prevention (1777) 1777
pregnancy (1772) 1772
drug administration schedule (1739) 1739
drug resistance (1664) 1664
pharmacokinetics (1656) 1656
incidence (1655) 1655
risk-factors (1638) 1638
administration, oral (1611) 1611
pneumonia (1602) 1602
resistance (1596) 1596
efficacy (1580) 1580
drug resistance in microorganisms (1560) 1560
epidemiology (1550) 1550
risk (1534) 1534
usage (1521) 1521
dosage and administration (1517) 1517
acute disease (1500) 1500
drug resistance, microbial (1490) 1490
antibacterial agents (1473) 1473
dose-response relationship, drug (1412) 1412
double-blind method (1408) 1408
dermatology (1407) 1407
antimicrobial agents (1389) 1389
helicobacter infections - drug therapy (1373) 1373
research article (1360) 1360
medicine (1357) 1357
patients (1350) 1350
recurrence (1337) 1337
disease (1322) 1322
antibiotic prophylaxis (1315) 1315
anti-bacterial agents - chemistry (1294) 1294
hospitals (1285) 1285
surgical wound infection - prevention & control (1276) 1276
prevalence (1257) 1257
bacteria - drug effects (1254) 1254
bacteremia (1252) 1252
double-blind (1251) 1251
infectious disease (1249) 1249
randomized controlled trials as topic (1231) 1231
respiratory system (1212) 1212
complications (1202) 1202
complications and side effects (1183) 1183
aminoglycosides (1167) 1167
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (26) 26
Online Resources - Online (13) 13
Thomas Fisher Rare Book - Rare Book (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Dentistry (Harry R Abbott) - Withdrawn (2) 2
St. Michael's Hospital - 2nd Floor (2) 2
UofT at Mississauga - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (44375) 44375
French (1526) 1526
German (1468) 1468
Japanese (790) 790
Russian (760) 760
Spanish (675) 675
Italian (357) 357
Polish (219) 219
Chinese (216) 216
Dutch (212) 212
Danish (138) 138
Swedish (129) 129
Norwegian (115) 115
Portuguese (92) 92
Czech (63) 63
Hungarian (59) 59
Romanian (55) 55
Finnish (44) 44
Bulgarian (34) 34
Hebrew (34) 34
Turkish (33) 33
Korean (26) 26
Serbian (22) 22
Croatian (16) 16
Ukrainian (14) 14
Lithuanian (9) 9
Slovak (7) 7
Greek (6) 6
Icelandic (5) 5
Afrikaans (4) 4
Arabic (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Handbook of antimicrobial therapy, ISSN 0025-732X
Journal
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 2010, Volume 105, Issue 4, pp. 259 - 273.e78
Journal Article
Journal Article
Food & function, ISSN 2042-650X, 2015, Volume 6, Issue 6, pp. 1875 - 1886
The methanolic extract of the wild edible mushroom Fr. (chanterelle) was analyzed for antioxidative, cytotoxic, antihypertensive and antibacterial activities.... 
PRI BIOS Applied Metabolic Systems | BIOS Applied Metabolic Systems | RAPID COLORIMETRIC ASSAY | CHEMICAL-CHARACTERIZATION | INHIBITION | ANTIOXIDANT ACTIVITIES | BIOCHEMISTRY & MOLECULAR BIOLOGY | FOOD SCIENCE & TECHNOLOGY | TOTAL PHENOLICS | IRON | GANODERMA-LUCIDUM | ANGIOTENSIN | CONVERTING-ENZYME-ACTIVITY | POLYSACCHARIDE EXTRACTS | Forests | Antioxidants - chemistry | Solvents - chemistry | Antioxidants - metabolism | Humans | Flavonoids - adverse effects | Fruiting Bodies, Fungal - growth & development | Iron Chelating Agents - metabolism | Angiotensin-Converting Enzyme Inhibitors - isolation & purification | Basidiomycota - metabolism | Dietary Supplements - analysis | Phytochemicals - adverse effects | Antineoplastic Agents - isolation & purification | Biological Products - adverse effects | Anti-Bacterial Agents - adverse effects | Basidiomycota - growth & development | Methanol - chemistry | Phytochemicals - chemistry | Anti-Bacterial Agents - isolation & purification | Basidiomycota - chemistry | Biological Products - isolation & purification | Angiotensin-Converting Enzyme Inhibitors - chemistry | Iron Chelating Agents - adverse effects | Iron Chelating Agents - isolation & purification | Biological Products - chemistry | Phenols - analysis | Enterococcus faecalis - metabolism | Antioxidants - isolation & purification | Fruiting Bodies, Fungal - metabolism | Biological Products - metabolism | Cell Line, Tumor | Phenols - chemistry | Flavonoids - chemistry | Flavonoids - analysis | Angiotensin-Converting Enzyme Inhibitors - metabolism | Iron Chelating Agents - chemistry | Antineoplastic Agents - metabolism | Antineoplastic Agents - adverse effects | Anti-Bacterial Agents - chemistry | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Dietary Supplements - adverse effects | Cell Line | Phytochemicals - analysis | Cell Survival | Anti-Bacterial Agents - metabolism | Enterococcus faecalis - growth & development | Phenols - metabolism | Antineoplastic Agents - chemistry | Phenols - adverse effects | Flavonoids - metabolism | Fruiting Bodies, Fungal - chemistry | Antioxidants - adverse effects | Phytochemicals - biosynthesis | Lipid Peroxidation | Montenegro
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
Journal Article
Expert review of anti-infective therapy, ISSN 1744-8336, 2014, Volume 6, Issue 5, pp. 593 - 600
Despite the constantly increasing need for new antimicrobial agents, antibiotic drug discovery and development seem to have greatly decelerated in recent years... 
aminoglycoside | Acinetobacter baumannii | multiple-drug resistant | fusidic acid | polymyxin B | Pseudomonas aeruginosa | chloramphenicol | fosfomycin | colistin | Colistin | Aminoglycoside | Fusidic acid | Chloramphenicol | Polymyxin B | Fosfomycin | Multiple-drug resistant | VENTILATOR-ASSOCIATED PNEUMONIA | NATURAL-PRODUCTS | RESISTANT STAPHYLOCOCCUS-AUREUS | ANTIBACTERIAL DRUG DISCOVERY | GRAM-NEGATIVE BACTERIA | INTENSIVE-CARE-UNIT | PSEUDOMONAS-AERUGINOSA | PHARMACOLOGY & PHARMACY | CYSTIC-FIBROSIS | CRITICALLY-ILL PATIENTS | TRIMETHOPRIM-SULFAMETHOXAZOLE | Fusidic Acid - administration & dosage | Humans | Drug Resistance, Bacterial | Drug Utilization | Anti-Bacterial Agents - therapeutic use | Aminoglycosides - administration & dosage | Colistin - therapeutic use | Anti-Bacterial Agents - adverse effects | Colistin - adverse effects | Fosfomycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Bacterial Infections - drug therapy | Fosfomycin - adverse effects | Colistin - administration & dosage | Fusidic Acid - adverse effects | Chloramphenicol - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Fusidic Acid - therapeutic use | Chloramphenicol - adverse effects | Anti-Bacterial Agents - classification | Fosfomycin - administration & dosage | Aminoglycosides - adverse effects | Anti-Bacterial Agents - administration & dosage | Aminoglycosides - therapeutic use | Chloramphenicol - administration & dosage | Drug resistance in microorganisms | Pseudomonas aeruginosa infections | Usage | Antibiotics | Research | Drug therapy | Health aspects | Risk factors | Index Medicus
Journal Article
Current Opinion in Anaesthesiology, ISSN 0952-7907, 06/2011, Volume 24, Issue 3, pp. 320 - 325
Journal Article